Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian Cancer

By Burger R.A.   DiSaia P.J.   Roberts J.A.   O'Rourke M.   Gershenson D.M.   Homesley H.D.   Lichtman S.M.   Barnes W.   Moore D.H.   Monk B.J.  

Gynecologic Oncology, Vol. 72, Iss. 2, 1999-02 ,pp. : 148-153

Elsevier

Access to resources Recommend Favorite

Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancer

By Alvarez Secord A.   Jones E. L.   Hahn C. A.   Petros W. P.   Yu D.   Havrilesky L. J.   Soper J. T.   Berchuck A.   Spasojevic I.   Clarke-Pearson D. L.   Prosnitz L. R.   Dewhirst M. W.  

International Journal of Hyperthermia, Vol. 21, Iss. 4, 2005-06 ,pp. : 333-347

Informa Healthcare

Access to resources Recommend Favorite

A Phase I Study of Intraperitoneal Interferon-α_2b and Intravenous cis-Platinum plus Cyclophosphamide Chemotherapy in Patients with Untreated Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Pilot Study

By Moore D.H.   Valea F.   Walton L.A.   Soper J.   Clarke-Pearson D.   Fowler Jr. W.C.  

Gynecologic Oncology, Vol. 59, Iss. 2, 1995-11 ,pp. : 267-272

Academic Press

Access to resources Recommend Favorite

Phase II Study of 96-hr Continuous-Infusion Etoposide and Doxorubicin with Bolus Cyclophosphamide in Refractory Epithelial Ovarian Cancer

By Fleming G.F.   Waggoner S.E.   Rotmensch J.   Skoog L.A.   Langhauser C.  

Gynecologic Oncology, Vol. 65, Iss. 1, 1997-04 ,pp. : 42-45

Elsevier

Access to resources Recommend Favorite